Original Article

Frequency of Urinary Tract Infections and Their Antibacterial Susceptibility among Chronic Kidney Disease Patients Undergoing Hemodialysis

Hidayatullah Memon[1], Om Parkash[2*], Vijia Kumar Gemnani[3]

ABSTRACT

OBJECTIVE: To investigate the prevalence and antibiotic resistance of uropathogenic bacteria among chronic kidney disease (CKD) patients undergoing hemodialysis.

METHODOLOGY: This descriptive, cross-sectional study was conducted at Chandka Medical College, Larkana, from May 2023 to September 2024. Using a convenient sampling technique, the study included 187 patients diagnosed with CKD, aged between 15 and 74 years of both genders, undergoing hemodialysis, including those with stone disease, neurogenic bladder dysfunction, or urinary tract foreign bodies. Patients with a history of urinary tract malignancy, congenital anomaly of the urogenital tract, recent antibiotic use or unwillingness to participate were excluded. Data was collected via a structured questionnaire. Urine samples were cultured on cystine-lactose-electrolyte-deficient (CLED) agar, and uropathogenic bacteria were identified using Gram staining and biochemical tests. Antibiotic susceptibility was determined using the Kirby-Bauer method, and the data were analysed with SPSS (version 24.0).

RESULTS: Majority of patients (51.2%) were aged 50–60 years. Urinary tract infections (UTIs) were identified in 84 (45%) patients. The most common pathogens were Escherichia coli (E. coli) (42.8%), Klebsiella spp. (35.7%), and Proteus spp. (21.4%). No significant association was observedbetween gender and the occurrence of urinary tract infection (UTI). Amikacin demonstrated 100% sensitivity against E. coli and Klebsiella spp. High resistance rates were observed for ceftazidime, norfloxacin, and amoxicillin.

CONCLUSION: UTIs are highly prevalent among CKD patients undergoing hemodialysis. The emergence of significant antimicrobial resistance (AR) highlights the need for routine susceptibility testing and strengthened antibiotic stewardship programs.

KEYWORDS: Chronic kidney disease, Urinary tract Infections, Uropathogenic bacteria, E. coli, Hemodialysis, Antibiotic resistance.

INTRODUCTION

Chronic kidney disease CKD is described as a persistent, irreversible derangement of kidney function, along with elevated serum creatinine levels for >3 months or the calculated glomerular filtration rate (GFR) <60 mL/min/1.73m^2. CKD is classified based on staging and grading[1]. The risk factors for the development of CKD consist of diabetes mellitus type 2, glomerulonephritis, hypertension, polycystic kidney diseases, renal vascular diseases, nephrolithiasis and vesicoureteral reflux[2].

CKD patients undergoing hemodialysis are at an increased risk of developing urinary tract infections (UTIs) due to several interrelated factors. CKD is associated with immune system dysfunction, including reduced leukocyte activity and altered cytokine production, which diminishes the body's ability to combat infections effectively[3]. In males with CKD on hemodialysis, additional factors, such as prostatic enlargement, contribute to urinary stasis, creating a favourable environment for microbial growth and recurrent infections[4].

Escherichia coli (E. coli), *Klebsiella spp*., *Proteus mirabilis*, Staphylococcus saprophyticus, and Staphylococcus *aureus* are common uropathogens, with *E. coli* being the most prevalent. While antibiotics are the standard treatment for UTIs, increasing multidrug resistance (MDR) among uropathogens, particularly in CKD patients, complicates therapeutic strategies[5].

METHODOLOGY

This descriptive cross-sectional study was conducted at the Department of Pathology and the Nephrology Department at Chandka Medical College, Shaheed Mohtarma Benazir Bhutto Medical University,

[1]*Department of Pathology, GMMC, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Pakistan*
[2]*Department of Pathology, CMC, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Pakistan*
[3]*Department of Community Medicine, CMC, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Pakistan*
Correspondence: *omparkash.smbbmu@gmail.com*
doi: 10.22442/jlumhs.2025.01232
Received: 16-01-2025 *Revised: 11-07-2025*
Accepted: 23-07-2025 *Published Online: 31-07-2025*

Larkana, between May 2023 and September 2024. The institutional review board (IRB) approved the study (Registration No. SMBBMU/OFF ERC/230). The study employed convenient sampling to enrol 187 CKD patients aged 15–74 years, of both genders, undergoing hemodialysis, including individuals with stone disease, neurogenic bladder dysfunction, or urinary tract foreign bodies. Patients with a history of urinary tract malignancy, congenital urogenital anomalies, recent antibiotic use, or those unwilling to participate were excluded. For demographic data, informed consent was obtained from all participants in accordance with ethical research standards.

A 10–30 ml random clean-catch midstream sample was obtained in sterile containers, labelled, and promptly transported to the Microbiology Lab at Chandka Medical College, Larkana, for immediate processing to preserve any uropathogenic bacteria.

Urine specimens were inoculated onto cystine-lactose -electrolyte-deficient (CLED) agar using a calibrated 1 µl wire loop for accurate colony counting. Plates were incubated at 37°C for 24–48 hours to promote bacterial growth. After incubation, colonies were visually examined and categorized as significant or non-significant based on colony count. Colonies were identified using morphology, Gram staining, and biochemical tests. Following identification, antibiotic resistance was assessed by the Kirby-Bauer disc diffusion method on Mueller-Hinton Agar, with results interpreted according to Clinical Laboratory Standards Institute (CLSI) and zone-diameter criteria (2009). Data were analyzed using SPSS (version 24.0)**.**

RESULTS

In this study, 187 urine culture samples from patients with CKD undergoing hemodialysis were analysed. The detection rate for Gram-negative organisms was 84 samples, yielding a prevalence of approximately 45%. The remaining 103 samples (55%) showed no bacterial growth, underscoring the overall frequency of UTIs in this patient cohort. Among the 84 culture-positive samples, *E. coli was identified as the most prevalent uropathogen, occurring in 36 cases, corresponding* to a frequency of 42.8%. *Klebsiella spp*. was found in 30 samples, representing a frequency of 35.7%, and Proteus spp. was detected in 18 cases, indicating a frequency of 21.4%.

The majority of patients (51.2%) were aged 50–60 years (**Table I**). In contrast, younger patients (20-30 years and 30-40 years) represent a smaller percentage of the population.

The gender analysis indicates a near-equal distribution of males (46.43%) and females (53.57%) (**Table I)**, with a chi-square test revealing no statistically significant difference in UTI incidence between genders (p = 0.513). This suggests that neither gender shows a clear predisposition to UTIs in this patient group.

The findings show a higher prevalence of UTIs among patients from rural areas (73%) compared to urban residents (26%) (**Table I)**. This highlights the potential impact of geographical and environmental factors on UTI incidence in CKD patients.

The data indicate that among patients with diabetes, females experience a higher rate of UTIs than males (**Table I)**. In cases of renal stones, there is a marked male predominance in UTI incidence. Additionally, all female patients with a history of post-partum hemorrhage were diagnosed with UTIs, suggesting a possible link that warrants further investigation.

ABS profiles of E. coli isolated from UTIs revealed varying sensitivity. Amikacin showed the highest sensitivity (100%), followed by fosfomycin (58%), tobramycin (75.8%), and gentamicin (63.6%). Intermediate susceptibility was observed for cefepime (39.4%) and ciprofloxacin (29.4%). Several antibiotics, including norfloxacin, cefaclor, amoxicillin, cephradine, and cefoperazone, showed low susceptibility, with all isolates resistant to the first four and 72.7% resistant to cefoperazone. Ceftazidime and Augmentin exhibited resistance rates of 60.6% and 35.7%, respectively, indicating emerging resistance (**Figure I**).

Table I: Demographic and Comorbidity Profile of Patients with CKD

Category	Subcategory	No. of Patients	Proportion (%)
Age Distribution	20-30 years	9	10.71
	30-40 years	8	9.52
	40-50 years	8	9.52
	50-60 years	43	51.2
	60-70 years	16	19.06
Gender Distribution	Male	39	46.43
	Female	45	53.57
Residence	Rural	62	73
	Urban	22	26
Comorbidities	Diabetes Mellitus	29	34.52
	Hypertensive Disease	23	27.38
	Renal Stones	17	20.24
	Post-partum Hemorrhage	15	17.86

Klebsiella spp. isolates showed complete sensitivity (100%) to amikacin and chloramphenicol. Fosfomycin had a moderate sensitivity rate (30%). Intermediate susceptibility was seen for tobramycin, gentamicin, cefepime, and ciprofloxacin, with rates ranging from 9% (cefepime) to 16% (ciprofloxacin). High resistance was observed for ceftazidime, norfloxacin, cefaclor, amoxicillin, cephradine, and cefoperazone, with complete resistance to ceftazidime (100%) (**Figure II**).

Proteus isolates exhibited high susceptibility to amikacin and chloramphenicol (<2% resistance). Fosfomycin showed moderate sensitivity (70%), while tobramycin and gentamicin had sensitivities of 76% and 52.2%, respectively. Intermediate susceptibility was noted for cefepime, ciprofloxacin, and Augmentin,

ranging from 14.8% (ciprofloxacin) to 33.3% (cefepime). High resistance was found for norfloxacin, cefaclor, amoxicillin, and cephradine, with complete resistance (100%) (**Figure III**).



Figure I. Antibacterial sensitivity profile of E. coli against different antibiotics



Figure II. Antibacterial sensitivity profile of Klebsiella spp. against different antibiotics



Figure III. Antibacterial sensitivity profile of *Proteus spp*. against various antibiotics

DISCUSSION

UTI is a term applied to a variety of clinical conditions ranging from the asymptomatic presence of bacteria in the urine to severe kidney infection with resultant sepsis[5]. CKD is considered a global public health burden, particularly in low- and middle-income countries[6].

The predominance of *E. coli* observed in our cohort aligns with global trends, identifying it as the leading cause of UTIs across various patient populations. Supporting these findings, a recent cross-sectional study conducted among 326 diagnosed CKD patients in the Department of Nephrology at Bangabandhu Sheikh Mujib Medical University reported that 79.4% of bacterial isolates were predominantly Gram-negative[7,8]. This finding aligns with the existing literature, which frequently identifies *E. coli* as the leading cause of UTIs[9].

Demographically, the concentration of UTIs among CKD patients aged 50–60 years highlights the vulnerability of older adults. Older adults with kidney disease are more prone to infections due to weakened immune systems and other health issues common with age[10]. This finding highlights the need for targeted monitoring and preventive strategies in older patients with CKD.

The absence of significant gender differences in UTI prevalence in this study supports literature suggesting that, among CKD patients, traditional gender-related anatomical risk differences may be attenuated by overriding factors such as overall health and lifestyle, which might be more influential in determining UTI risk for individuals with kidney disease[11].

Geographic disparities emerged prominently in this study, with a markedly higher prevalence of UTIs among patients residing in rural areas, suggesting barriers to healthcare access in rural areas, which can delay diagnosis and treatment of infections, potentially exacerbating health outcomes[12]. This finding calls for further investigation into the barriers rural CKD patients face in accessing timely medical care.

It was observed that diabetes in women was associated with increased UTI risk, while kidney stones were more strongly associated with UTIs in men. These findings align with existing knowledge that the impact of diabetes on increased UTI risk is well established, as hyperglycemia can impair immune function and facilitate bacterial growth[13]. Furthermore, the complete diagnosis of UTIs in all female patients with a history of post-partum hemorrhage suggests a potential connection that warrants further exploration in future studies.

The antimicrobial susceptibility analysis of *E. coli* isolates revealed a clear gradient of effectiveness across tested agents. Amikacin exhibited complete sensitivity (100%), reaffirming its role as a reliable first -line therapy, consistent with prior studies highlighting its sustained activity even against resistant strains[14]. The moderate susceptibility observed for fosfomycin, tobramycin, and gentamicin suggests they can still be helpful in some cases. In contrast, cefepime and ciprofloxacin showed lower susceptibility, reflecting the global increase in resistance to fluoroquinolones and cephalosporins, driven by mutations in target enzymes and β-lactamase production[15]. These antibiotics are commonly used to treat UTIs, and the relatively low susceptibility rates raise serious concern[16].

Furthermore, several antibiotics, including norfloxacin, cefaclor, amoxicillin, cephradine, and cefoperazone, showed low susceptibility, with high resistance rates. Ceftazidime and Augmentin also showed significant resistance. This is consistent with studies showing that overuse of these agents in both clinical and

community settings has led to the evolution of resistant strains[17]. This indicates a growing challenge in using these antibiotics, driven by increasing resistance among *E. coli* strains.

The susceptibility profiles of *Klebsiella spp.* isolates revealed both reassuring and concerning patterns. Amikacin and chloramphenicol demonstrated complete sensitivity (100%), corroborating previous reports of their sustained efficacy against *Klebsiella pneumoniae* infections[20]. However, fosfomycin showed moderate sensitivity, suggesting that these antibiotics may remain viable options in some cases, though their effectiveness can vary depending on local resistance patterns. The moderate sensitivity to fosfomycin is also consistent with other reports, which have noted varying susceptibility rates to this antibiotic among Klebsiella isolates[21]. Notably, high resistance rates were observed against several commonly used antibiotics, with ceftazidime showing complete ineffectiveness - an alarming finding given its frequent use for *Klebsiella* infections[22]. These findings highlight the challenges in treating *Klebsiella spp*. Infections with standard antibiotics are due to widespread resistance.

The susceptibility patterns of *Proteus spp.* revealed notable contrasts. Amikacin and chloramphenicol maintained excellent efficacy, with resistance rates below 2%, consistent with prior studies reporting sensitivity exceeding 95% [23,24]. Similar to *E. coli* and *Klebsiella*, fosfomycin demonstrated moderate sensitivity, suggesting a role in selective cases. Intermediate susceptibility was observed for cefepime, ciprofloxacin, and Augmentin, indicating potential but limited use in treatment. High resistance rates were observed for norfloxacin, cefaclor, amoxicillin, and cephradine, with complete resistance noted in some cases. Studies have consistently shown high resistance rates among *Proteus* isolates to these antibiotics, particularly in healthcare settings where antibiotic use is more prevalent[25,26]. This underscores the challenge of using these antibiotics effectively against Proteus spp[27]. The findings underscore the dynamic nature of AR among uropathogens, necessitating ongoing surveillance and targeted antimicrobial stewardship efforts. Tailored treatment strategies based on local resistance patterns are crucial to optimize therapeutic outcomes and mitigate the spread of resistance in clinical settings.

CONCLUSION

This study demonstrates a high prevalence of urinary tract infections among CKD patients undergoing hemodialysis, with E. coli being the predominant pathogen. Although amikacin retained excellent efficacy, substantial resistance to commonly used antibiotics was observed. These findings emphasize the importance of routine antimicrobial susceptibility testing and the implementation of antibiotic stewardship strategies to optimize treatment outcomes in this high-risk population.

Ethical permission: Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Pakistan, ERC approval letter No. SMBBMU/OFF ERC/230.

Conflict of Interest: No conflict of interest.

Financial Disclosure / Grant Approval: No external funding was obtained from any source.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Memon H: Conducted the experiments, collected and analyzed the data, and prepared the initial draft of the manuscript.

Parkash O: Conceptualized the study, supervised the research activities, and reviewed and edited the manuscript.

Gemnani VK: Contributed to the methodology and provided supervision for data collection and analysis.

REFERENCES

1. Xu X, Nie S, Zhang A. Acute kidney injury among hospitalized children in China. Clin J Am Soc Nephrol. 2018; 13(12): 1791-1800. doi: 10.2215/CJN.00800118.
2. Voyer L. History of childhood kidney disease and risk of adult end-stage renal disease. Arch Argent Pediatr. 2018; 116(4): e636-e637. doi: 10.1002/ppul.23948.
3. Shankar M, Narasimhappa S, Madhura NS. Urinary tract infection in chronic kidney disease population: a clinical observational study. Cureus. 2021; 13(1): e12486. doi: 10.7759/cureus.12486.
4. Chhakchhuak M, Chaturvedy M, Agarwal J, Tak V, Bajpai NK. Retrospective analysis of spectrum of infections and antibiotic resistance pattern in chronic kidney disease patients on maintenance hemodialysis in a tertiary care centre in North India. Indian J Nephrol. 2023; 33(3): 177-82. doi: 10.4103/ijn.ijn_238_21.
5. Dimitrijevic Z, Paunovic G, Tasic D, Mitic B, Basic D. Risk factors for urosepsis in chronic kidney disease patients with urinary tract infections. Sci Rep. 2021; 11(1): 14414. doi: 10.1038/s41598-021-93912-3.
6. V. K, George A, M. V. Study of clinical profile and risk factors associated with febrile urinary tract infection in preschool children. Int J Contemp Pediatr. Published online 2016; 243-246. doi: 10.18203/2349-3291.ijcp20160168.
7. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022; 12(1): 7-11. doi: 10.1016/j.kisu.2021.11.003.
8. Haque Sumon AH. S, Al-Mahmood MR, Islam KA, et al. Multidrug resistance urinary tract infection in chronic kidney disease patients: An observational study. Cureus. Published online 2023. doi: 10.7759/cureus.38571

9. Tekce H, Kin Tekce B, Aktas G, Tanrisev M, Sit M. The evaluation of red cell distribution width in chronic hemodialysis patients. Int J Nephrol. 2014; 1: 754370. doi: 10.1155/2014/754370.
10. Jalil MB, Al Atbee MYN. The prevalence of multiple drug-resistant Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections. J Clin Lab Anal. 2022; 36 (9). doi: 10.1002/jcla.24619.
11. Fried, L. P. The impact of aging on chronic kidney disease and its complications. J Am Geriatr Soc. 2021; 69(1): 123-129.
12. Kelly JT, Su G, Zhang L, Qin X, Marshall S, González-Ortiz A et al. Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis. J Am Soc Nephrol. 2021; 32(1): 239-53. doi: 1681/ASN.2020030384.
13. Baker R, Sweeney D. Geographic disparities in access to healthcare: implications for chronic kidney disease management. Health Serv Res. 2020; 55(3): 324-332.
14. Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. J Infect Chemother. 2021; 27(8): 1131-6. doi: 10.1016/ j.jiac.2021.05.012.
15. Chou A, Welch E, Hunter A, Trautner BW. Antimicrobial treatment options for difficult-to-treat resistant gram-negative bacteria causing cystitis, pyelonephritis, and prostatitis: a narrative review. Drugs. 2022; 82(4): 407-38. doi: 10.1007/s40265-022-01676-5.
16. Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009–2011. Clin Ther. 2013; 35: 872–877. doi: 10.1016/j.clinthera.2013.03.022.
17. Totsika M, Gomes Moriel D, Idris A. Uropathogenic Escherichia coli mediated urinary tract infection. Curr Drug Targets. 2012; 13(11): 1386-1399. doi: 10.2174/138945012803530206.
18. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem, Ther Adv Drug Saf. 2014; 5(6): 229–241. doi: 10.1177/2042098614554919.
19. Lorenzoni VV, Rubert FdC, Rampelotto RF, Hörner R. Increased antimicrobial resistance in Klebsiella pneumoniae from a University Hospital in Rio Grande do Sul, Brazil. Rev Soc Bras Med Trop. 2018; 51(5): 676-9. doi: 10.1590/0037-8682-0362-2017.
20. Bologna E, Licari LC, Manfredi C, Ditonno F, Cirillo L, Fusco GM et al. . Carbapenem-resistant Enterobacteriaceae in urinary tract infections: from biological insights to emerging therapeutic alternatives. Medicina. 2024; 60(2): 214. doi: 10.3390/medicina60020214.
21. Sorlozano A, Jimenez-Pacheco A, De Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: A 7-year surveillance study. Am J Infect Control. Control 2014; 42: 1033–1038. doi: 10.1016/j.ajic.2014.06.013.
22. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. JAMA. 2016; 316(11): 1193-204. doi: 10.1001/jama.2016. 11764.
23. Chen D, Zhang Y, Huang J. The analysis of microbial spectrum and antibiotic resistance of uropathogens isolated from patients with urinary stones. Int J Clin Pract. 2018; 72(6): e13205. doi: 10.1111/ijcp.13205.13205
24. Kamil TD, Jarjes SF. Isolation, identification, and antibiotics susceptibility determination of Proteus species obtained from various clinical specimens in Erbil city. Polytech J. 2019; 9(2): 86-92. doi: 10.25156/ptj.v9n2y2019.pp86-92.
25. Lescat M, Poirel L, Tinguely C, Nordmann P. A resazurin reduction-based assay for rapid detection of polymyxin resistance in Acinetobacter baumannii and Pseudomonas aeruginosa. J Clin Microbiol. 2019; 57: e01563 -18. doi: 10.1128/ JCM. 01563-18.
26. Yang JH, Sheng WH, Hsueh PR. Antimicrobial susceptibility and distribution of extended-spectrum β-lactamases, AmpC β-lactamases and carbapenemases among Proteus, Providencia and Morganella isolated from global hospitalised patients with intra-abdominal and urinary tract infections: Results of the study for monitoring antimicrobial resistance trends (SMART), 2008-2011. J Glob Antimicrob Resist. 2020; 22: 398-407. doi: 10.1016/j.jgar. 2020.04.011.
27. Thapa TB, Pokhrel S, Lamichhane A. Prevalence and antibiogram of bacteria causing urinary tract infection among patients with chronic kidney disease. Open Med. 2023; 18(1). doi: 10.1515/ med-2023-0824.